BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-25 out of over 1000 found
  Current Search:  clinic: 34325, phase: 12415, trial: 18924     

HTML
100%
GeoVax Labs provides update on vaccine trials progress
- US biopharmaceutical company GeoVax Labs Inc (OTC: GOVX) gave yesterday an update on its vaccine trials progress.

CEO Robert McNally said that the HIV/AIDS population continues to grow at an alarming rate, 60,000 new infections annually, and that's...

Therapeutics Daily:  Feb 9 2010 12:30PM
Matching: clinic phase trial
Find similar documents
HTML
100%
GeoVax Labs, Inc. Begins Enrollment At Final Site For Preventative Vaccine; Next Step Is To Submit IND Application For Therapeutic Vaccine To FDA
GeoVax Labs, Inc.

(OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, provided an update on its vaccine ...

Medical News Today:  Feb 9 2010 4:13PM
Matching: clinic phase trial
Find similar documents
HTML
100%
GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
ATLANTA, Feb.

8 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc.

(OTC Bulletin Board: GOVX.OB) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious...

Yahoo! Canada:  Feb 9 2010 1:32AM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.

9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd.

, a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody...

Interest!ALERT:  Feb 9 2010 3:16PM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
(GlobeNewswire via COMTEX) ----XOMA Ltd.

(Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody...

FOXBusiness.com:  Feb 9 2010 1:32PM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.

9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd.

(Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of...

Therapeutics Daily:  Feb 9 2010 1:19PM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.

9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd.

(Nasdaq:XOMA - News), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical ...

Yahoo! Canada:  Feb 9 2010 1:13PM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.

9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd.

(Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of...

DMN Newswire:  Feb 9 2010 12:39PM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052
BERKELEY, Calif., Feb.

9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd.

(Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of...

GlobeNewswire via MSN Money:  Feb 9 2010 12:25PM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.

9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd.

(Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial...

Street Insider:  Feb 9 2010 12:21PM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.

9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd.

(Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial...

Street Insider:  Feb 9 2010 12:19PM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.

9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd.

(Nasdaq:XOMA - News), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical ...

GlobeNewswire via Yahoo!:  Feb 9 2010 12:17PM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.

9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd.

(Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of...

Stockwatch:  Feb 9 2010 12:12PM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.

9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd.

, a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody...

NewsBlaze:  Feb 9 2010 12:11PM
Matching: clinic phase trial
Find similar documents
HTML
100%
GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA (AEGiS)
GeoVax Labs, Inc.

Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA PRNewswire - February 8, 2010 http://www.aegis.org/news/pr/2010/PR100210.html -- Hires Clinical Research...

AEGIS:  Feb 9 2010 12:38AM
Matching: clinic phase trial
Find similar documents
HTML
100%
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for the Modified REGENESIS Phase IIb Stroke Trial
(MARKETWIRE via COMTEX) ----Stem Cell Therapeutics Corp.

("SCT" or the "Company") (TSX VENTURE: SSS) announced today it has been advised by the Data Safety Monitoring Board ("DSMB") that its third and final regularly scheduled safety analysis has been...

FOXBusiness.com:  Feb 9 2010 3:11PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for the Modified REGENESIS Phase IIb Stroke Trial
CALGARY, ALBERTA--(Marketwire - Feb.

9, 2010) - Stem Cell Therapeutics Corp.

("SCT" or the "Company") (TSX VENTURE: SSS) announced today it has been advised by the Data Safety Monitoring Board ("DSMB") that its third and final regularly scheduled safety...

Street Insider:  Feb 9 2010 2:04PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds To Erroneous Report About Planned Phase III Study For Patient
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds To Erroneous Report About Planned Phase III Study For Patients With Colorectal Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites Compare and save on surgery Medical and ...
MediLexicon:  Feb 9 2010 3:58AM
Matching: clinic phase trial
Find similar documents
HTML
100%
XOMA (XOMA) Begins Enrollment for XOMA 052 Phase 2b
XOMA Ltd.

(NASDAQ: XOMA) announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody candidate, XOMA 052, in Type 2 diabetes patients.

The randomized, placebo-controlled trial will be...

Street Insider:  Feb 9 2010 1:22PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Penwest Initiates Second Phase IIa Clinical Trial for A0001
PATTERSON, N.Y., Feb.

9, 2010 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co.

today announced that it has initiated a Phase IIa clinical trial for A0001 in patients with the A3243G mitochondrial DNA point mutation and evidence of impaired...

Interest!ALERT:  Feb 9 2010 5:30PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring B
MARKETWIRE Stem Cell Therapeutics Corp.

('SCT' or the 'Company') (TSX VENTURE: SSS) announced today it has been advised by the Data Safety Monitoring Board ('DSMB') that its third and final regularly scheduled safety analysis has been completed and the DSMB...

Genetic Engineering News:  Feb 9 2010 3:52PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Cerus Corporation Reports Positive Outcome Of Phase 1 Clinical Trial Of INTERCEPT Red Blood Cells
Cerus Corporation (NASDAQ:CERS) announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated cells...
Medical News Today:  Feb 9 2010 8:58PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood Cells
Data Supports Advancement of Product Development CONCORD, Calif.--(BUSINESS WIRE)--Feb 9, 2010 - Cerus Corporation (NASDAQ:CERS) announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary...
Pharma Live:  Feb 9 2010 6:16PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring B
CALGARY, ALBERTA -- (MARKET WIRE) -- 02/09/10 -- Stem Cell Therapeutics Corp.

('SCT' or the 'Company') (TSX VENTURE: SSS) announced today it has been advised by the Data Safety Monitoring Board ('DSMB') that its third and final regularly scheduled safety...

Therapeutics Daily:  Feb 9 2010 2:55PM
Matching: clinic phase trial
Find similar documents
HTML
100%
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for the Modif
(Marketwire via COMTEX) -- Stem Cell Therapeutics Corp.

("SCT" or the "Company") (TSX VENTURE: SSS | Quote | Chart | News | PowerRating) announced today it has been advised by the Data Safety Monitoring Board ("DSMB") that its third and final regularly...

TradingMarkets:  Feb 9 2010 2:42PM
Matching: clinic phase trial
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.